Plaque Psoriasis

For many patients, chronic idiopathic urticaria can be a debilitating condition affecting them at all hours of the day and making living with the condition very difficult. Because of this, the need for newer, more effective treatments is driving the field forward at a rapid pace.

Patients with active psoriatic arthritis treated with secukinumab for 2 years in the FUTURE-1 trial experienced sustained decreases in disease activity and symptoms, leading to improvements in physical function and quality of life.

A new model that combines real-world prices with outcome data from both controlled trials and clinical practice indicates that the immediate use of tumor necrosis factor inhibitors (anti-TNFs) is a cost-effective way to achieve good first-year outcomes in patients newly diagnosed with both plaque psoriasis and psoriatic arthritis.

The process for treatment of plaque psoriasis can be a very involved process depending on their history with the condition and other issues they may have as well. This can include psoriatic arthritis.

As newer treatment options hit the market for plaque psoriasis patients may have more questions about the best options for them. This is part of the importance of communicating with patients throughout the treatment process.

For patients diagnosed with plaque psoriasis there can be other health issues to consider as well. This can include heart attack, stroke, and obesity as well as obesity and others.

As with many conditions, the kind of care a patient receives can depend on where they live. This can be especially true for dermatology patients needing things like phototherapy. Other factors, like cost and fear, can also impede the treatment process.

Despite the life of a patient with eczema being in many ways similar to that of a patient with psoriasis, their options for treatment are not nearly as robust as the other dermatologic condition.

As patients go through the process of treating their plaque psoriasis, there can be different levels of success depending on a number of situations. As a result, measuring success can be a challenge as well.

With most cases of plaque psoriasis being diagnosed in adolescence the treatment and diagnosis can be a delicate process, especially when parents are involved.

As new treatments for plaque psoriasis are developed the field as a whole is taking a new look at the condition. However, there are still challenges to overcome in diagnosis and treatment.

It was not long ago that patients diagnosed with plaque psoriasis would require a month-long hospital stay for a short-lived treatment of the condition.

Many psoriasis patients wish they were better informed of the significant impact their skin condition would have on their physical and mental health, according to results from Psoriasis in America 2016, a Health Union national survey.

The US Food and Drug Administration's (FDA's) Arthritis Advisory Committee recently voted unanimously to recommend the approval of biosimilars to adalimumab (Humira) and etanercept (Enbrel).

A new study found that female psoriasis patients have a fourfold increased risk of developing Crohn’s disease (CD).

A family history of heart attacks increases psoriasis patients’ odds of having heart attacks and strokes.

Novartis conducted a global survey of 8,338 patients with moderate-to-severe psoriasis across 31 countries to assess patients’ perceptions of what constitutes “clear skin.â€

While psoriasis has long been linked to other inflammatory conditions, there is little information about psoriasis-related hospitalization.

In patients diagnosed with psoriasis, disease severity has been strongly associated with developing a higher risk of comorbidities affecting the kidney, liver, and pancreas.

Patients suffering from psoriasis are at increased risk of developing serious infections.

It is frustrating, to say the least, when your patients take their frustrations out on you. And, as if having to deal with an angry patient isn’t bad enough, providers now have to worry about the threat of legal action more than ever before.

After the FDA’s March approval of ixekizumab (Taltz/ Eli Lilly and Company), researchers recently confirmed the psoriasis treatment was beneficial even after 60 weeks.

Biologic therapies, such as tumor necrosis factor (TNF) inhibitors, can potentially mitigate symptoms of depression and insomnia in patients with psoriasis and psoriatic arthritis.

Nearly 50% of Medicare patients taking biologic therapies for moderate-to-severe plaque psoriasis stop treatment within a year, reported a study by the Perelman School of Medicine at the University of Pennsylvania.

Researchers have concluded that there is a small but significant genetic component to the observed connection between high body mass index (BMI) and psoriasis.

A new study has uncovered a potential shared genetic source between psoriasis and obesity, which could also address a connection among psoriasis, type 2 diabetes, and body mass index (BMI).

Patients afflicted with psoriasis have higher odds of developing abdominal aortic aneurysms.

The FDA has approved Inflectra (infliximab-dyyb/Celltrion, Inc), the biosimilar for Remicade (infliximab) for the treatment of patients suffering from serious autoimmune diseases.

Men afflicted with psoriasis are more likely to suffer from erectile dysfunction.

The FDA has approved ixekizumab (Taltz/Eli Lilly) for moderate to severe plaque psoriasis. It is administered by injection.